Ruben Smith1,2, Moa Wibom3, Daria Pawlik2, Elisabet Englund4, Oskar Hansson2,5. 1. Department of Neurology, Skåne University Hospital, Lund, Sweden. 2. Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden. 3. Department of Cognitive Medicine, Ängelholm Hospital, Ängelholm, Sweden. 4. Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. 5. Memory Clinic, Skåne University Hospital, Malmö, Sweden.
Abstract
Importance: In Alzheimer disease (AD), tau filaments form neuronal inclusions in neurites (neuropil threads) and in somata (neurofibrillary tangles), and neurite tau pathology constitutes the most common pathology. Positron emission tomography (PET) ligands have been developed to detect in vivo tau pathology in AD. However, the association of AD tau pathology post mortem with in vivo tau PET retention has not been established. Therefore, there is a need to investigate the associations of tau PET with postmortem tau pathology in AD. Objective: To study the association of regional in vivo retention of the tau PET ligand [18F]flortaucipir (previously known as AV1451) with the density of tau neuropathology in the corresponding brain regions in a patient with AD. Design, Setting, and Participants: The patient was a man in his 40s with AD caused by a PSEN1 mutation. Between May 2015 and December 2016, he underwent 2 [18F]flortaucipir PET scans at Lund University Hospital, Lund, Sweden. Postmortem analysis was performed 12 months after the last PET scan. Tau pathology was assessed using phosphorylated tau (AT8) immunohistochemistry and Gallyas silver staining. In addition to the regional total tau pathology burden, the density of tau-positive neurites and intrasomal tau tangles were quantified using a stereology-based method. Further, β-amyloid-containing plaques were detected using 4G8 immunohistochemistry. Data were analyzed between January 2018 and August 2018. Main Outcomes and Measures: Regional standardized uptake value ratios of [18F]flortaucipir were compared with the amount of tau pathology in the corresponding brain areas. Results: In this patient, the clinical disease symptoms progressed rapidly in life, paralleled with an annual increase of tau PET retention of 20% to 40% in many cortical regions. Compared with postmortem immunohistochemistry, regional in vivo uptake of [18F]flortaucipir was correlated with the density of tau-positive neurites (AT8: rs = 0.87; P < .001; Gallyas: rs = 0.92; P < .001), intrasomal tau tangles (AT8: rs = 0.65; P = .01; Gallyas: rs = 0.84; P < .001), and total tau burden (AT8: rs = 0.84; P < .001; Gallyas: rs = 0.82; P < .001). No correlations between [18F]flortaucipir and β-amyloid pathology were found. Conclusions and Relevance: These results indicate that [18F]flortaucipir PET retention is a robust in vivo measure of the total AD tau burden.
Importance: In Alzheimer disease (AD), tau filaments form neuronal inclusions in neurites (neuropil threads) and in somata (neurofibrillary tangles), and neurite tau pathology constitutes the most common pathology. Positron emission tomography (PET) ligands have been developed to detect in vivo tau pathology in AD. However, the association of AD tau pathology post mortem with in vivo tau PET retention has not been established. Therefore, there is a need to investigate the associations of tau PET with postmortem tau pathology in AD. Objective: To study the association of regional in vivo retention of the tau PET ligand [18F]flortaucipir (previously known as AV1451) with the density of tau neuropathology in the corresponding brain regions in a patient with AD. Design, Setting, and Participants: The patient was a man in his 40s with AD caused by a PSEN1 mutation. Between May 2015 and December 2016, he underwent 2 [18F]flortaucipir PET scans at Lund University Hospital, Lund, Sweden. Postmortem analysis was performed 12 months after the last PET scan. Tau pathology was assessed using phosphorylated tau (AT8) immunohistochemistry and Gallyas silver staining. In addition to the regional total tau pathology burden, the density of tau-positive neurites and intrasomal tau tangles were quantified using a stereology-based method. Further, β-amyloid-containing plaques were detected using 4G8 immunohistochemistry. Data were analyzed between January 2018 and August 2018. Main Outcomes and Measures: Regional standardized uptake value ratios of [18F]flortaucipir were compared with the amount of tau pathology in the corresponding brain areas. Results: In this patient, the clinical disease symptoms progressed rapidly in life, paralleled with an annual increase of tau PET retention of 20% to 40% in many cortical regions. Compared with postmortem immunohistochemistry, regional in vivo uptake of [18F]flortaucipir was correlated with the density of tau-positive neurites (AT8: rs = 0.87; P < .001; Gallyas: rs = 0.92; P < .001), intrasomal tau tangles (AT8: rs = 0.65; P = .01; Gallyas: rs = 0.84; P < .001), and total tau burden (AT8: rs = 0.84; P < .001; Gallyas: rs = 0.82; P < .001). No correlations between [18F]flortaucipir and β-amyloid pathology were found. Conclusions and Relevance: These results indicate that [18F]flortaucipir PET retention is a robust in vivo measure of the total AD tau burden.
Authors: Lennart Thurfjell; Johan Lilja; Roger Lundqvist; Chris Buckley; Adrian Smith; Rik Vandenberghe; Paul Sherwin Journal: J Nucl Med Date: 2014-08-21 Impact factor: 10.057
Authors: T W Mitchell; J Nissanov; L Y Han; E J Mufson; J A Schneider; E J Cochran; D A Bennett; V M Lee; J Q Trojanowski; S E Arnold Journal: J Histochem Cytochem Date: 2000-12 Impact factor: 2.479
Authors: Rik Ossenkoppele; Gil D Rabinovici; Ruben Smith; Hanna Cho; Michael Schöll; Olof Strandberg; Sebastian Palmqvist; Niklas Mattsson; Shorena Janelidze; Alexander Santillo; Tomas Ohlsson; Jonas Jögi; Richard Tsai; Renaud La Joie; Joel Kramer; Adam L Boxer; Maria L Gorno-Tempini; Bruce L Miller; Jae Y Choi; Young H Ryu; Chul H Lyoo; Oskar Hansson Journal: JAMA Date: 2018-09-18 Impact factor: 56.272
Authors: Michael Schöll; Samuel N Lockhart; Daniel R Schonhaut; James P O'Neil; Mustafa Janabi; Rik Ossenkoppele; Suzanne L Baker; Jacob W Vogel; Jamie Faria; Henry D Schwimmer; Gil D Rabinovici; William J Jagust Journal: Neuron Date: 2016-03-02 Impact factor: 17.173
Authors: Ira Driscoll; Juan C Troncoso; Gay Rudow; Jitka Sojkova; Olga Pletnikova; Yun Zhou; Michael A Kraut; Luigi Ferrucci; Chester A Mathis; William E Klunk; Richard J O'Brien; Christos Davatzikos; Dean F Wong; Susan M Resnick Journal: Acta Neuropathol Date: 2012-08-05 Impact factor: 17.088
Authors: Michael Schöll; Rik Ossenkoppele; Olof Strandberg; Sebastian Palmqvist; Jonas Jögi; Tomas Ohlsson; Ruben Smith; Oskar Hansson Journal: Brain Date: 2017-09-01 Impact factor: 13.501
Authors: Ruben Smith; Moa Wibom; Tomas Olsson; Douglas Hägerström; Jonas Jögi; Gil D Rabinovici; Oskar Hansson Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472
Authors: Milos D Ikonomovic; William E Klunk; Eric E Abrahamson; Chester A Mathis; Julie C Price; Nicholas D Tsopelas; Brian J Lopresti; Scott Ziolko; Wenzhu Bi; William R Paljug; Manik L Debnath; Caroline E Hope; Barbara A Isanski; Ronald L Hamilton; Steven T DeKosky Journal: Brain Date: 2008-03-12 Impact factor: 13.501
Authors: Clifford R Jack; Heather J Wiste; Christopher G Schwarz; Val J Lowe; Matthew L Senjem; Prashanthi Vemuri; Stephen D Weigand; Terry M Therneau; Dave S Knopman; Jeffrey L Gunter; David T Jones; Jonathan Graff-Radford; Kejal Kantarci; Rosebud O Roberts; Michelle M Mielke; Mary M Machulda; Ronald C Petersen Journal: Brain Date: 2018-05-01 Impact factor: 13.501
Authors: Val J Lowe; Geoffry Curran; Ping Fang; Amanda M Liesinger; Keith A Josephs; Joseph E Parisi; Kejal Kantarci; Bradley F Boeve; Mukesh K Pandey; Tyler Bruinsma; David S Knopman; David T Jones; Leonard Petrucelli; Casey N Cook; Neill R Graff-Radford; Dennis W Dickson; Ronald C Petersen; Clifford R Jack; Melissa E Murray Journal: Acta Neuropathol Commun Date: 2016-06-13 Impact factor: 7.801
Authors: Val J Lowe; Emily S Lundt; Sabrina M Albertson; Hoon-Ki Min; Ping Fang; Scott A Przybelski; Matthew L Senjem; Christopher G Schwarz; Kejal Kantarci; Bradley Boeve; David T Jones; R Ross Reichard; Jessica F Tranovich; Fadi S Hanna Al-Shaikh; David S Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Melissa E Murray Journal: Alzheimers Dement Date: 2020-01-04 Impact factor: 21.566
Authors: William G Mantyh; Salvatore Spina; Alex Lee; Leonardo Iaccarino; David Soleimani-Meigooni; Elena Tsoy; Taylor J Mellinger; Harli Grant; Lawren Vandevrede; Renaud La Joie; Orit Lesman-Segev; Stephanie Gaus; Katherine L Possin; Lea T Grinberg; Bruce L Miller; William W Seeley; Gil D Rabinovici Journal: JAMA Neurol Date: 2020-04-01 Impact factor: 18.302
Authors: David N Soleimani-Meigooni; Leonardo Iaccarino; Renaud La Joie; Suzanne Baker; Viktoriya Bourakova; Adam L Boxer; Lauren Edwards; Rana Eser; Maria-Luisa Gorno-Tempini; William J Jagust; Mustafa Janabi; Joel H Kramer; Orit H Lesman-Segev; Taylor Mellinger; Bruce L Miller; Julie Pham; Howard J Rosen; Salvatore Spina; William W Seeley; Amelia Strom; Lea T Grinberg; Gil D Rabinovici Journal: Brain Date: 2020-12-05 Impact factor: 13.501
Authors: Kamalini G Ranasinghe; Cathrine Petersen; Kiwamu Kudo; Danielle Mizuiri; Katherine P Rankin; Gil D Rabinovici; Maria Luisa Gorno-Tempini; William W Seeley; Salvatore Spina; Bruce L Miller; Keith Vossel; Lea T Grinberg; Srikantan S Nagarajan Journal: Alzheimers Dement Date: 2021-04-21 Impact factor: 21.566